Tranilast treats cold-related hypertension by reducing the expression of NLRP3 inflammasome
Hui Yu1
Yun Zhou1
Yu Duan1
Yunlong Gao1
Ning Fang1
Jiawei Zhang1
Yue Li2
1.Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin,150001,China2.Department of Cardiology,the First Affiliated Hospital,Harbin Medical University,Harbin,150001,China;Key Laboratory of Cardiac Diseases and Heart Failure,Harbin Medical University,Harbin,150001,China;Institute of Metabolic Disease,Heilongjiang Academy of Medical Science,Harbin,150081,China
摘要：Objective: Cold exposure is associated with increased prevalence of hypertension and the related severe cardiovascular events. Aberrant activation of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome plays an important role in the development of hypertension. Tranilast (TR), an inhibitor of NLRP3, provides a useful pharmacological probe for exploring the role of NLRP3 in pathogenesis associated with inflammation and its potential application as a therapeutic agent. This study was designed to examine the effects of TR on NLRP3 and hypertension in rats exposed to cold environment to simulate the frigid-zone conditions. Methods and results: Sprague Dawley (SD) rats were exposed to moderate cold temperature (4±1℃), and then were randomized to receive TR or vehicle for 3 weeks, while the control group was raised under rat room temperature (RT, 23±1℃). We found that cold exposure substantially increased blood pressure, NLRP3 inflammasome level, and fibrosis in aorta, which were reversed by TR. Conclusion: TR has an anti-hypertensive property in cold environment, and this beneficial action is likely conferred by its inhibitory effects on inflammation and fibrosis. These findings suggest TR as a potential drug for the treatment of cold-induced hypertension.
机标关键词：
论文发表日期：2021-04-30
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：7( 95-101 )
英文信息